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Summary
 
We explore here if vaccination with DNA encoding an autoantigenic peptide can suppress au-
toimmune disease. For this purpose we used experimental autoimmune encephalomyelitis
(EAE), which is an autoaggressive disease in the central nervous system and an animal model
for multiple sclerosis. Lewis rats were vaccinated with DNA encoding an encephalitogenic T
cell epitope, guinea pig myelin basic protein peptide 68–85 (MBP68–85), before induction of
EAE with MBP68–85 in complete Freund’s adjuvant. Compared to vaccination with a control
DNA construct, the vaccination suppressed clinical and histopathological signs of EAE, and re-
duced the interferon 
 
g
 
 production after challenge with MBP68–85. Targeting of the gene
product to Fc of IgG was essential for this effect. There were no signs of a Th2 cytokine bias.
Our data suggest that DNA vaccines encoding autoantigenic peptides may be useful tools in
controlling autoimmune disease.
 
D
 
NA vaccination can generate protective immunity
against infectious disease (1) and experimental cancer
(2). Potential advantages with DNA vaccination are (
 
a
 
)
prolonged, endogenous expression of antigen (3), (
 
b
 
) long-
term immunity with efficient generation of both CD8
 
1
 
 cy-
totoxic T cells and CD4
 
1
 
 Th cells (1, 4), and (
 
c
 
) possibili-
ties to modulate the Th1 or Th2 response by alteration of
the vaccination protocol (5). DNA vaccination is also po-
tentially applicable to autoimmune disease, as has been
done in one particular model of experimental autoimmune
encephalomyelitis (EAE) (4). Various forms of EAE are
prototype animal models for Th1 type organ-specific au-
toimmunity and in many respects resemble human multiple
sclerosis (6). The disease can be generated in a number of
species by immunization with myelin proteins (7) and has
been used extensively for evaluation of preventive as well
as therapeutic strategies to alter autoimmune disease (8–11).
In the Pl/J (H-2u) mouse EAE model, in which DNA
vaccination has been tested thus far, TCRBV8S2 is domi-
nantly expressed by encephalitogenic T cells, and immuni-
zation with plasmid DNA encoding this TCRBV-chain
suppresses EAE, probably through induction of Th2 cyto-
kines (4). However, there is no preferential TCR usage in
many autoimmune conditions. Furthermore, a Th2 bias is
not always beneficial; e.g., in Marmoset monkeys, myelin/
oligodendrocyte glycoprotein–induced EAE was aggravated
after induction of Th2 immunity (12). Therefore, we
wanted to test alternative approaches for DNA vaccination
against EAE by targeting the myelin Ag instead of the
TCR, and to achieve a potential downregulation of the
pathogenic autoimmune responses without a Th2 bias. We
used Lewis rat EAE, in which guinea pig myelin basic pro-
tein peptide 68–85 (MBP68–85) acts as a strong, disease-
inducing T cell epitope (7). We constructed DNA vaccines
coding for this amino acid sequence to examine if they
were able to alter the course and immune response of a
subsequently induced disease. In addition, we explored
whether targeting the expressed protein to Fc of IgG by fu-
sion to a protein A analogue (13) could enhance the tolero-
genic ability of the construct.
 
Materials and Methods
 
Peptides and Mitogen.
 
Greater than 99% pure peptides HYGSLP-
QKSQRSQDENPV from guinea pig sequence MBP68–85 and
VHFFKNIVTPRTP from rat/guinea pig sequence MBP89–101
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were synthesized by the Fmoc/HBTU strategy (A. Engstrom,
University of Uppsala, Uppsala, Sweden). Con A was purchased
from Sigma Chemical Co. (St. Louis, MO).
 
Plasmid Construction.
 
pZZ/MBP68–85: A 94-bp fragment
containing a murine heavy chain IgG signal sequence (ss) was li-
gated upstream and in frame of a 385-bp fragment encoding ZZ
(13). Directly downstream of the coding sequence of ZZ and up-
stream of the stop codon, seven AvaI–AvaI fragments encoding
MBP68–85 were ligated in frame. pMBP68–85: A linker, con-
taining AvaI and BbsI sites and stop codon, was ligated down-
stream and in frame of the ss fragment. Directly upstream of the
stop codon, five AvaI–AvaI MBP68–85 fragments were ligated in
frame. The ss/ZZ/MBP68–85 fragment and the ss/MBP68–85
fragment were cloned into the eukaryotic expression vector pCI
(Promega, Madison, WI). pZZ: A fragment containing ss and ZZ
in frame was cloned into pCI. pCIss: The 94-bp ss fragment was
cloned into pCI. Expression is driven by immediate/early human
CMV enhancer/promoter. 
 
Escherichia coli
 
 host was XL1-Blue
(Stratagene Corp., La Jolla, CA).
 
Plasmid Preparation.
 
Plasmid DNA was prepared by Qiagen
plasmid preparation protocol. Endotoxins were removed in an
additional step (Endofree buffer set; Qiagen, Santa Clarita, CA).
 
Plasmid DNA Injections and Cardiotoxin Pretreatment.
 
5–6-wk-old
Lewis (RT1) male rats (Harlan Netherlands, Zeist, The Netherlands)
were injected with 100 
 
m
 
l of 10 mM cardiotoxin (Latoxan, Rosans,
France) into the 
 
Musculii gastrocnemii
 
. 7 d later, the rats were injected
with 800 
 
m
 
g DNA at 2.0 mg/ml in PBS, divided into four 200-
 
m
 
g
injections administered in the 
 
Musculii tibialii
 
 and 
 
M. gastrocnemii
 
 of
pZZ/MBP68–85, pZZ, pMBP68–85, or pCIss.
 
EAE Induction and Clinical Evaluation.
 
5 wk after DNA vacci-
nation, rats were injected intradermally at the base of the tail with
200 
 
m
 
l inoculum containing 1:1 200-
 
m
 
g MBP68–85 in saline
emulsified in CFA, consisting of IFA (Sigma Chemical Co.) and
0.5 mg heat-inactivated 
 
Mycobacterium tuberculosis
 
 (strain H37 RA;
Difco Laboratories, Detroit, MI). Animals were clinically scored
and weighed daily. The symptoms were scored as follows: grade
1, tail weakness or tail paralysis; grade 2, hind leg paraparesis;
grade 3, hind leg paralysis; grade 4, complete paralysis (tetraplegy),
moribund state, or death.
 
Determination of MBP68–85–specific IgG and IgG-Isotype Responses.
 
ELISA plates were coated with 10 
 
m
 
g/ml of MBP68–85 in car-
bonate buffer pH 9.6. Rat sera were diluted 1:10, 1:50, 1:250, 1:
1,250, 1:6,250, or 1:31,250 in PBS-M (5% milk powder, 0.2%
Tween 20 in PBS). Wells were incubated for 2 h with sera,
washed in PBS-T (0.2% Tween 20 in PBS), and incubated for 2 h
with 1:1,000 alkaline phosphatase (AKP)–conjugated goat anti–
rat IgG (Biosource International, Camarillo, CA), monoclonal
AKP-conjugated mouse anti–rat IgG1, IgG2a, or IgG2b (Phar-
Mingen, San Diego, CA), respectively, in PBS-M. To determine
IgG2c levels, wells were incubated with 1:1,000 biotinylated
mouse anti–rat IgG2c (Biosource International) in PBS-M for 1 h
followed by a 1-h incubation with 1:1,000 AKP-streptavidin in
PBS-T. pNPP (Sigma Chemical Co.) was used as substrate and
OD was read at 405 nm.
 
Cell Preparation and Culture.
 
Inguinal lymph nodes were torn
apart in DMEM (GIBCO BRL, Gaithersburg, MD). Mononu-
clear cells (MNCs) were resuspended in complete medium con-
taining DMEM supplemented with 1% rat serum, 1% penicillin/
streptomycin (GIBCO BRL), 1% glutamine (GIBCO BRL), and
50 
 
m
 
M mercaptoethanol (GIBCO BRL), and flushed through a
70-
 
m
 
m plastic strainer (Becton Dickinson, Mountain View, CA),
adjusted to 2 
 
3
 
 10
 
6
 
 cells/ml, and cultured at 37
 
8
 
C in a humidi-
fied atmosphere containing 5% CO
 
2
 
.
 
Proliferation Assays.
 
2 
 
3
 
 10
 
5
 
 MNCs were cultivated with or
without the relevant antigens in complete medium for 60 h and
subsequently pulsed with 0.5 
 
m
 
Ci methyl–[
 
3
 
H]thymidine ([
 
3
 
H]TdR,
Amersham, Buckinghamshire, UK) for 12 h. DNA was collected
on glass fiber filters (Skatron, Sterling, VA) and [
 
3
 
H]TdR incor-
poration was measured in a beta counter.
 
In Situ Hybridization for Cytokine mRNA Transcribing MNCs.
 
In situ hybridization was performed as previously described (14).
As positive controls, Con A–stimulated cells were assessed for
cytokine mRNA content.
 
ELISA to Assess Cytokine Production in Vitro.
 
ELISA kits for
detection of secreted IFN-
 
g
 
, IL-4, and IL-10 were purchased
from Biosource International. Supernatants from MNCs, which
had been incubated at a concentration of 2 
 
3
 
 10
 
6
 
 cells/ml with
or without relevant antigens or Con A, were analyzed. The pro-
cedure was performed as recommended by the manufacturer.
 
In Vivo CD8
 
1
 
 T Cell Depletion.
 
Depletion of CD8
 
1
 
 T cells
in vivo was performed as previously described (14). 0.5 mg of
mAb Ox-8 in 500 
 
m
 
l PBS were injected intraperitoneally on day
0, before induction of disease, and on days 7 and 13 after immu-
nization. Depletion was confirmed by FACS
 
Ò
 
 (Becton Dickin-
son) analysis on day 18 after immunization.
 
Histopathological Evaluation.
 
Histological evaluation was per-
formed by standard neuropathological procedures and immuno-
cytochemistry for T cells and macrophages as previously de-
scribed (15).
 
Statistics.
 
Abnormally distributed groups were tested with the
Mann-Whitney U-test. Normally distributed groups were tested
with Student’s 
 
t
 
 test.
 
Results and Discussion
 
We constructed DNA vaccines encoding MBP68–85 in
tandem, with or without fusion to a dimerized synthetic
analogue Z of the IgG-binding B domain of staphylococcal
protein A (13), pZZ/MBP68–85 (Fig. 1), and pMBP68–
85. We hypothesized that binding of the hybrid gene prod-
uct to IgG could alter the presentation of MBP68–85 and
thereby affect its tolerogenicity with consequences for the
quality of the ensuing immune response. As negative con-
trols we constructed DNA vaccines with or without ZZ
but lacking the MBP68–85 inserts, pZZ and pCIss.
A survey of the effects of DNA vaccination on clinical
and histopathological signs of EAE is presented in Table 1.
Lewis rats were injected intramuscularly with cardiotoxin
and 7 d later with 800 
 
m
 
g of either pZZ/MBP68–85 or
pZZ. 5 wk later, the rats were challenged with MBP68–85
in CFA. pZZ-injected control rats displayed a classical
monophasic EAE course with disease onset on day 9 after
immunization, ascending paraparesis with maximum clini-
cal disease on days 12–14, followed by recovery. In con-
trast, pZZ/MBP68–85-injected rats showed a drastically al-
tered disease course with reduced mean accumulated EAE
score and reduced peak disease severity (Fig. 2 
 
A
 
 and Table 1).
To study if fusion of MBP68–85 to ZZ was essential for
suppression of EAE, rats were treated with pMBP68–85.
As control we vaccinated with pCIss. As opposed to the
pZZ/MBP68–85 vaccine, treatment with pMBP68–85
failed to significantly suppress EAE (Fig. 2 
 
B
 
 and Table 1).
The exact molecular mechanism for the drastic effect of 
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ZZ/MBP68–85 fusion on tolerogenicity is currently under
study. Potentially, ZZ might affect distribution and half life
of MBP68–85. ZZ binds to B cells in vivo (16). Uptake of
the secreted fusion protein and subsequent presentation on
MHC class I and II molecules on B cells might alter the en-
suing immune response after subsequent immunogen chal-
lenge (17). Indeed, targeting of MBP peptide to B cell sur-
face–exposed IgD suppresses EAE (10), and conjugating Ag
to Fc of IgG induces tolerance (18).
Clinical signs of EAE and degree of inflammation within
the central nervous system (CNS) may dissociate (19).
Therefore it was also important to study the degree of con-
comitant CNS inflammation. On day 12 after immuniza-
tion, 8 pZZ/MBP68–85-treated and 8 pZZ-treated rats
were killed for histopathological evaluation. A semiquanti-
tative evaluation of coded brains and spinal cords revealed
that the mean inflammatory index in the spinal cord of the
rats treated with pZZ/MBP68–85 was strongly reduced;
1.1 compared to 4.0 in the pZZ-treated control group (Ta-
ble 1). The pathology was characterized by perivenous in-
flammation. In both groups, inflammatory infiltrates con-
sisted of T cells and, to a lesser extent, macrophages. The
inflammatory infiltrates were present in highest density in
the spinal cord and brain stem, whereas forebrain areas and
peripheral nerves were less affected.
To study the immune mechanisms involved in suppres-
sion of EAE after DNA vaccination, we next studied the
profile of T cell reactivity to MBP68–85. MBP-specific
IFN-
 
g
 
–secreting CD4
 
1
 
 T cells are crucial for disease in-
duction of MBP-induced EAE (20). Antigen-induced
IFN-
 
g
 
 and proliferative responses in vitro of lymph node
cells (LNCs) from MBP68–85-immunized and DNA-vac-
cinated rats were measured on day 12 after immunization.
Interestingly, the proliferative response to MBP68–85 of T
cells derived from the regional lymph nodes in the pZZ/
MBP68–85-treated and the pZZ-treated groups was not
significantly different (Fig. 3 
 
A
 
). On the contrary, IFN-
 
g
Figure 1. Plasmid map of DNA vaccine pZZ/MBP68–85. Seven re-
peats of oligonucleotides encoding autoantigen MBP68–85 were cloned
downstream of a murine signal sequence fused to a dimerized synthetic
analogue of the IgG-binding B domain of staphylococcal protein A gene,
ZZ. As a negative control, a corresponding DNA vaccine coding for ZZ
was constructed (pZZ). To investigate the role of ZZ in the protection
from EAE, a DNA construct lacking ZZ, but encoding autoantigen
MBP68–85 in tandem, was constructed (pMBP68–85). pCIss, encoding
the signal sequence alone, was used as a negative control for pMBP68–85.
 
Table 1.
 
Effect of DNA Vaccination on Clinical and Histopathological Signs of EAE
 
Experiment Treatment
 
n
 
Clinical data Histopathology
Mean
accumulated
EAE score
 
P
 
Mean
maximum
EAE score
 
P
 
Mean
inflammatory
index
 
P
 
1 pZZ/MBP68–85 8 3.4 0.0001 1.1 0.02
pZZ 8 15.2 2.6
2 pZZ/MBP68–85 8 4.5 0.001 0.8 0.028
pZZ 8 14.6 2.6
pZZ/MBP68–85 8 ND ND 1.1 0.04
pZZ 8 ND ND 4.0
pMBP68–85 8 9.1 NS 1.4 NS
pCIss 8 12.0 2.4
pZZ/MBP68–85
 
*
 
8 5.4 0.006 0.6 0.028
pZZ
 
*
 
8 13.6 2.1
The experiments were done on two occasions. Rats received the DNA vaccines 5 wk before induction of EAE with MBP68–85 in CFA. In exper-
iment 2, 16 rats were killed on day 12 after immunization for evaluation of histopathology and immune responses. Mean accumulated EAE score is
the cumulative disease score on day 21 after immunization (score obtained daily [0–4]). Mean maximum EAE score designates the average peak score of
clinical disease at any time during the disease course, here on days 12–14 after immunization. Mean inflammatory index measures the degree of inflam-
mation in spinal cord of rats killed on day 12 after immunization. 
 
P
 
 values were calculated with Mann-Whitney’s test. 
 
NS
 
, not significant at 0.05 level.
 
*
 
Rats were injected with mAb OX-8 on days 0, 7, and 13 after immunization to deplete CD8
 
1
 
 cells in vivo. 
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production in response to MBP68–85 was dramatically re-
duced in the protected pZZ/MBP68–85-treated rats, both
at the level of the numbers of cells transcribing IFN-
 
g
 
mRNA (
 
P
 
 
 
,
 
0.0001; Fig. 3 
 
B
 
) and of the amount of IFN-
 
g
 
in cell culture supernatants from MBP68–85-exposed T
cells (
 
P
 
 
 
,
 
0.001; Fig. 3 
 
C
 
), compared to the pZZ-treated
rats. Furthermore, we measured IL-4 and IL-10 production
in response to MBP68–85 to assess if the observed effects of
pZZ/MBP68–85 could be due to induction of a Th2-
biased autoimmune response. However, we could not de-
tect any differences in the number of cells transcribing IL-4
or IL-10 mRNA (data not shown) or in the levels of IL-10
(Fig. 3 
 
D
 
) or IL-4 (undetectable) in cell culture superna-
tants between rats treated with pZZ/MBP68–85 or with
pZZ, indicating no measurable alteration of the Th1/Th2
balance of encephalitogenic T cells in our system.
Figure 2. (A) Effect of DNA
vaccination on mean clinical EAE
score after treatment with pZZ/
MBP68–85 or pZZ and subse-
quent induction of EAE with
MBP68–85. (B) Effect of DNA
vaccine lacking ZZ gene. Mean
clinical EAE score of rats after
treatment with DNA vaccine en-
coding MBP68–85 but not ZZ,
pMBP68–85, or negative control
pCIss after subsequent induction
of EAE (n 5 8/group) with
MBP68–85. (C) Effect of CD81 cell depletion on mean clinical EAE score of rats after treatment with pZZ/MBP68–85 or pZZ after subsequent induc-
tion of EAE with MBP68–85. CD81 cell depletion with mAb OX-8 was performed on days 0, 7, and 14 after immunization.
Figure 3. (A) T cell proliferation 6 SEM after 72 h of in vitro exposure to antigen MBP68–85 (0.1–100 mg/ml) or Con A at 1 mg/ml. Peripheral
LNCs were collected at 12 d after immunization from rats treated with pZZ/MBP68–85 or pZZ before immunization with MBP68–85. SI, Stimulation
index. Conc designates concentration. (B) IFN-g mRNA transcription 12 d after immunization of rats treated with pZZ/MBP68–85 or pZZ before im-
munization with MBP68–85. ****P ,0.0001. Measurement of the number of IFN-g transcribing cells per 105 LNCs by in situ hybridization after a 72-h
exposure to MBP68–85, MBP89–101, or Con A. (C) IFN-g and (D) IL-10 expression at 12 d after immunization of rats treated with DNA vaccine
pZZ/MBP68–85 or pZZ before immunization with MBP68–85. Supernatants from LNCs exposed in vitro to MBP68–85 or Con A for 72 h were tested
in cytokine ELISA for the presence of IFN-g and IL-10, respectively. **P ,0.001.1547 Lobell et al. Brief Definitive Report
To study the effects of DNA vaccination on B cell im-
munity, we next measured MBP68–85-specific serum anti-
bodies. At day 12 after immunization, total serum levels of
IgG and IgG2a MBP68–85-specific antibodies were re-
duced and MBP68–85-specific IgG1, IgG2b, and IgG2c
responses were similar in the pZZ/MBP68–86-treated
group compared with controls (Fig. 4). The MBP68–85-
specific IgG isotype data further strengthened the lack of a
Th2 shift, since the IgG1 levels in pZZ/MBP68–85-
treated compared with pZZ-treated rats were not en-
hanced. Our data suggest that the functional differentiation of
MBP68–85-specific encephalitogenic CD41 T cells is altered
by the preceding DNA vaccination. pZZ/MBP68–85 did
not reduce expansion of MBP68–85-specific immunocom-
petent cells, but changed their ability to secrete the proin-
flammatory cytokine IFN-g after Ag challenge. Since the
encephalitogenicity of MBP68–85-specific T cells in an
immunocompetent host strongly depends on their ability
to secrete proinflammatory cytokines (20), the alteration in
responsiveness to secrete IFN-g after Ag-exposure might
be one important reason for the protection of rats vacci-
nated with pZZ/MBP68–85. Our findings are partly con-
sistent with a recent study by Marusic and Tonegawa
where intraperitoneal injection of MBP peptide 1–17 in
MBP 1–17 TCR transgenic mice induced tolerance by
dampening Th1 type as well as Th2 type responses (21).
Potentially, the lack of induction of a Th2 type response
with our tolerogenic protocol is advantageous, since Th2
type responses can result in increased levels of secreted au-
toantibodies, which can be detrimental under certain con-
ditions (12).
DNA vaccines are efficient inducers of CD81 T cell–
mediated immunity (1), and CD81 cells can be protective
in EAE (14). For this reason we were interested to study
the role of CD81 cells in conferring protection after DNA
vaccination with pZZ/MBP68–85. We depleted the CD81
cells of pZZ or pZZ/MBP68–85-treated rats after immu-
nogen challenge with MBP68–85 in CFA on days 0, 7, and
13 after immunization with the mAb Ox-8 in vivo (14).
On day 18 after immunization, CD81 cells were reduced
to 14% of the numbers of nontreated controls, as assessed
by FACSÒ analysis. The Ox-8 treatment did not affect the
protective effect of pZZ/MBP68–85 on MBP68–85-induced
EAE. We did not rule out that CD81 cells could not have
any impact on the initial priming of the protective immu-
nity after injection of the DNA vaccines, but we demon-
strated that the suppression after active immunization with
MBP68–85 was not mediated by CD81 cells.
Bacterial immunostimulatory DNA sequences (ISS) can
function as Th1-promoting adjuvants (22) and are neces-
sary for effective DNA vaccination against b-galactosidase
(23). The vector backbone of our DNA vaccines contain
three ISS with the AACGTT sequence, known to induce
IFN-g production by NK cells and IL-12 production by B
cells, and to induce IL-12 and TNF-a production by mac-
rophages in vitro (24). The dramatic reduction of IFN-g
production after vaccination with pZZ/MBP68–85 makes
it unlikely that these ISS would induce IL-12 production.
However, preliminary data (Lobell, A., unpublished obser-
vations) reveal that the protective effect of pZZ/MBP68–85 is
abolished after replacing pZZ/MBP68–85s vector back-
bone with a vector lacking the AACGTT motifs. Studies
regarding the potential of ISS in protection against autoim-
mune disease are warranted, and are ongoing in our labora-
tory.
The vaccination effect discussed in this paper was re-
corded for one particular immunodominant T cell epitope
in the Lewis rat. We will determine if this vaccination pro-
tocol also affects the encephalitogenic responses to other
epitopes of MBP or even other myelin antigens, as has
been described in oral tolerance (8) or in altered peptide
ligand therapy (9). In these studies, there is circumstantial
evidence that production of type 2 cytokines (8, 9) and
TGF-b (8) is instrumental for a disease downregulatory re-
sponse resulting in dampening of disease-promoting cells of
whatever specificity. The lack of induction of a Th2-biased
immune response in our system would predict epitope
specificity and no bystander suppression. If true, successful
application of the principle of DNA vaccination to the
treatment of human autoimmune disease would then re-
quire knowledge of a particular, disease-relevant T cell
epitope. It is also possible that the autoimmune disease may
be driven by a set of different epitopes even from different
myelin proteins (25). In view of the MHC influence on
many human organ-specific inflammatory diseases, it is
possible that a hierarchy of a restricted set of different
epitopes may be relevant to disease. If so, and if they are
defined, the present DNA vaccination protocol does allow
construction of vaccines covering broad ranges of different
epitopes.
Figure 4. Mean MBP68–85-
specific IgG and IgG isotype re-
sponses at 1:50 serum dilution.
Rats received the DNA vaccines
5 wk before induction of EAE
with MBP68–85. Rat sera were
collected from rats killed on day
12 after immunization. *P ,0.03.
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